Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Notice of Results
By: Nasdaq / GlobeNewswire - 18 Oct 2018Back to overview list

Shire to announce third quarter 2018 results

Dublin, Ireland – October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), will announce third quarter 2018 earnings on Thursday November 1, 2018.

Results press release will be issued at:12:00 GMT / 08:00 EDT
Investor conference call time:14:00 GMT / 10:00 EDT

Live conference call for investors:
Flemming Ornskov, MD, M.P.H., Chief Executive Officer and Thomas Dittrich, Chief Financial Officer will host the investor and analyst conference call at 10:00 am EDT / 14:00 GMT.

The details of the conference call are as follows:

UK dial in:0800 358 9473 or +44 333 300 0804
US dial in:1 855 857 0686 or 1 631 913 1422
International Access Numbers:Click here
Password/Conf ID:28705371 #
Live Webcast:Click here

Replay:
A replay of the presentation will be made available, subject to approval by the UK Takeover Panel, for two weeks by phone and for three months by webcast.  Replay information made available will be contained on the Investor Relations section of Shire’s website at http://investors.shire.com/.

For further information please contact:

Investor Relations  
Christoph Brackmannchristoph.brackmann@shire.com+41 41 288 4129
Sun Kimsun.kim@shire.com+1 617 588 8175
Scott Burrowsscott.burrows@shire.com+41 41 288 4195
   
Media  
Katie Joycekjoyce@shire.com +1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics. 

Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.

www.shire.com

Related companies:ShangPharma Corp (SHP) | Shire Pharmaceuticals Ireland Ltd
Copyright 2018 Nasdaq / GlobeNewswire Back to overview list
to the top ↑